Can ginkgo biloba alter Alzheimer's blood signs?

NCT ID NCT07579689

Not yet recruiting Disease control Sponsor: Hanyang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily 240 mg dose of Ginkgo biloba extract can change certain blood markers linked to Alzheimer's disease in people with mild cognitive impairment. Over 6 months, 120 participants will be randomly assigned to receive either Ginkgo biloba or a placebo. The main goal is to see if the supplement affects levels of p-tau217 and other proteins in the blood, which may indicate changes in disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ginkgo biloba extract (240 mg daily)
What this could lead to: If it works, this could show that Ginkgo biloba affects Alzheimer's-related blood markers, pointing toward a possible way to slow disease progression.
What could go wrong: This is a small, early-phase trial focused on biomarkers, not clinical outcomes. Ginkgo biloba has not been proven to treat Alzheimer's, and results may not lead to a clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE MILD COGNITIVE IMPAIRMENT

More trials for these conditions

Other studies related to the condition(s) this trial covers.